ID: ALA4205338

Max Phase: Preclinical

Molecular Formula: C26H21N5OS

Molecular Weight: 451.56

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCc1ccc([C@H]2c3[nH]c4ccccc4c(=O)c3CN2c2ncc(-c3ccccn3)cn2)s1

Standard InChI:  InChI=1S/C26H21N5OS/c1-2-17-10-11-22(33-17)24-23-19(25(32)18-7-3-4-9-21(18)30-23)15-31(24)26-28-13-16(14-29-26)20-8-5-6-12-27-20/h3-14,24H,2,15H2,1H3,(H,30,32)/t24-/m0/s1

Standard InChI Key:  IFMLEMDUMAPODC-DEOSSOPVSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 451.56

Molecular Weight (Monoisotopic): 451.1467

AlogP: 5.11

#Rotatable Bonds: 4

Polar Surface Area: 74.77

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 12.40

CX Basic pKa: 3.99

CX LogP: 5.70

CX LogD: 5.70

Aromatic Rings: 5

Heavy Atoms: 33

QED Weighted: 0.41

Np Likeness Score: -0.89

References

1. Zheng H, Li L, Sun B, Gao Y, Song W, Zhao X, Gao Y, Xie Z, Zhang N, Ji J, Yuan H, Lou H..  (2018)  Design and synthesis of furyl/thineyl pyrroloquinolones based on natural alkaloid perlolyrine, lead to the discovery of potent and selective PDE5 inhibitors.,  150  [PMID:29505934] [10.1016/j.ejmech.2018.02.039]

Source

Source(1):

• Scientific Literature